ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Alternative Sunitinib Scheduling for mRCC

Eric Jonasch, MD
Published Online:1:55 PM, Tue March 28, 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.